Repository logo
Communities & Collections
All of DSpace
  • English
  • العربية
  • বাংলা
  • Català
  • Čeština
  • Deutsch
  • Ελληνικά
  • Español
  • Suomi
  • Français
  • Gàidhlig
  • हिंदी
  • Magyar
  • Italiano
  • Қазақ
  • Latviešu
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Српски
  • Svenska
  • Türkçe
  • Yкраї́нська
  • Tiếng Việt
Log In
New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Jain, Sonika"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Results Per Page
  • Sort Options
  • No Thumbnail Available
    Item
    Comprehensive Update on Synthetic Aspects of Bosentan Derivatives
    (Bentham Science Publishers, 2022-05-11T00:00:00) Panchal, Jigar; Panchal, Ashima; Jain, Sonika; Jain, Pankaj Kumar; Dwivedi, Jaya; Sharma, Swapnil
    Bosentan and its analogues were first reported as endothelin (ET) receptor antagonists in US patent No. 5, 292,740 in 1994. Bosentan synthesis has been reported by employing different methods from the reaction between (4,6-dichloro-5-(2-methoxyphenoxy)-2,2'-bipyrimidine and 4-(tert-butyl) benzenesulfonamide and 4-(tert-butyl)-N-(6-chloro-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl) benzenesulfonamide in the form of different salts like potassium salt, ammonium salt, sodium salt, and free, on its reaction with ethylene glycol. Several changes have been observed in the chemistry of the involved intermediate synthesis, particularly coupling chemistry, to produce bosentan derivatives with high purity and yield. � 2023 Bentham Science Publishers.
  • No Thumbnail Available
    Item
    A Literature Review of Pulmonary Arterial Hypertension (PAH)
    (Bentham Science Publishers, 2022-02-18T00:00:00) Panchal, Ashima; Panchal, Jigar; Jain, Sonika; Dwivedi, Jaya
    In 1891, German doctor E. Romberg was the first to report PAH. It is widespread throughout the world, but it is particularly problematic in India and other developing countries. Pulmonary arterial hypertension (PAH) is characterised by an increase in pulmonary arterial pressure as well as the emergence of progressive symptoms, such as a loss of functional ability, shortness of breath, and fatigue. Blood flows from the right side of the heart to the lungs through the pulmonary arteries. Pulmonary arterial pressure refers to the pressure in the arteries of the lungs (PAH). It necessitates immediate treatment because high blood pressure in the lungs causes the right side of the heart to work much harder, increasing the risk of heart failure. This article aimed to provide brief information about the prevalence, pathology, classification, and different therapies of PAH. � 2022 Bentham Science Publishers.

DSpace software copyright © 2002-2025 LYRASIS

  • Privacy policy
  • End User Agreement
  • Send Feedback
Repository logo COAR Notify